BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 28241424)

  • 1. Exome Sequencing in a Family with Luminal-Type Breast Cancer Underpinned by Variation in the Methylation Pathway.
    van der Merwe N; Peeters AV; Pienaar FM; Bezuidenhout J; van Rensburg SJ; Kotze MJ
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28241424
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Concolino P; Gelli G; Rizza R; Costella A; Scambia G; Capoluongo E
    Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31336956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Whole-exome sequencing and targeted gene sequencing provide insights into the role of PALB2 as a male breast cancer susceptibility gene.
    Silvestri V; Zelli V; Valentini V; Rizzolo P; Navazio AS; Coppa A; Agata S; Oliani C; Barana D; Castrignanò T; Viel A; Russo A; Tibiletti MG; Zanna I; Masala G; Cortesi L; Manoukian S; Azzollini J; Peissel B; Bonanni B; Peterlongo P; Radice P; Palli D; Giannini G; Chillemi G; Montagna M; Ottini L
    Cancer; 2017 Jan; 123(2):210-218. PubMed ID: 27648926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of hereditary cancer syndromes by using a panel of genes: novel and multiple pathogenic mutations.
    Tsaousis GN; Papadopoulou E; Apessos A; Agiannitopoulos K; Pepe G; Kampouri S; Diamantopoulos N; Floros T; Iosifidou R; Katopodi O; Koumarianou A; Markopoulos C; Papazisis K; Venizelos V; Xanthakis I; Xepapadakis G; Banu E; Eniu DT; Negru S; Stanculeanu DL; Ungureanu A; Ozmen V; Tansan S; Tekinel M; Yalcin S; Nasioulas G
    BMC Cancer; 2019 Jun; 19(1):535. PubMed ID: 31159747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic medicine and risk prediction across the disease spectrum.
    Kotze MJ; Lückhoff HK; Peeters AV; Baatjes K; Schoeman M; van der Merwe L; Grant KA; Fisher LR; van der Merwe N; Pretorius J; van Velden DP; Myburgh EJ; Pienaar FM; van Rensburg SJ; Yako YY; September AV; Moremi KE; Cronje FJ; Tiffin N; Bouwens CS; Bezuidenhout J; Apffelstaedt JP; Hough FS; Erasmus RT; Schneider JW
    Crit Rev Clin Lab Sci; 2015; 52(3):120-37. PubMed ID: 25597499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequency of pathogenic germline mutation in CHEK2, PALB2, MRE11, and RAD50 in patients at high risk for hereditary breast cancer.
    Kim H; Cho DY; Choi DH; Oh M; Shin I; Park W; Huh SJ; Nam SJ; Lee JE; Kim SW
    Breast Cancer Res Treat; 2017 Jan; 161(1):95-102. PubMed ID: 27783279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of ACMG-Guideline-Based Variant Classification of Cancer Susceptibility and Non-Cancer-Associated Genes in Families Affected by Breast Cancer.
    Maxwell KN; Hart SN; Vijai J; Schrader KA; Slavin TP; Thomas T; Wubbenhorst B; Ravichandran V; Moore RM; Hu C; Guidugli L; Wenz B; Domchek SM; Robson ME; Szabo C; Neuhausen SL; Weitzel JN; Offit K; Couch FJ; Nathanson KL
    Am J Hum Genet; 2016 May; 98(5):801-817. PubMed ID: 27153395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Whole exome sequencing combined with integrated variant annotation prediction identifies asymptomatic Tangier disease with compound heterozygous mutations in ABCA1 gene.
    Tada H; Kawashiri MA; Nohara A; Saito R; Tanaka Y; Nomura A; Konno T; Sakata K; Fujino N; Takamura T; Inazu A; Mabuchi H; Yamagishi M; Hayashi K
    Atherosclerosis; 2015 Jun; 240(2):324-9. PubMed ID: 25875382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Family specific genetic predisposition to breast cancer: results from Tunisian whole exome sequenced breast cancer cases.
    Hamdi Y; Boujemaa M; Ben Rekaya M; Ben Hamda C; Mighri N; El Benna H; Mejri N; Labidi S; Daoud N; Naouali C; Messaoud O; Chargui M; Ghedira K; Boubaker MS; Mrad R; Boussen H; Abdelhak S;
    J Transl Med; 2018 Jun; 16(1):158. PubMed ID: 29879995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RAD50 germline mutations are associated with poor survival in BRCA1/2-negative breast cancer patients.
    Fan C; Zhang J; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
    Int J Cancer; 2018 Oct; 143(8):1935-1942. PubMed ID: 29726012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utilization of Whole Exome Sequencing to Identify Causative Mutations in Familial Congenital Heart Disease.
    LaHaye S; Corsmeier D; Basu M; Bowman JL; Fitzgerald-Butt S; Zender G; Bosse K; McBride KL; White P; Garg V
    Circ Cardiovasc Genet; 2016 Aug; 9(4):320-9. PubMed ID: 27418595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RAD50 and NBS1 are not likely to be susceptibility genes in Chinese non-BRCA1/2 hereditary breast cancer.
    He M; Di GH; Cao AY; Hu Z; Jin W; Shen ZZ; Shao ZM
    Breast Cancer Res Treat; 2012 May; 133(1):111-6. PubMed ID: 21811815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of Novel Breast Cancer Risk Loci.
    Chan CHT; Munusamy P; Loke SY; Koh GL; Wong ESY; Law HY; Yoon CS; Tan MH; Yap YS; Ang P; Lee ASG
    Cancer Res; 2017 Oct; 77(19):5428-5437. PubMed ID: 28775167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of familial breast cancer in Saudi Arabia.
    Merdad A; Gari MA; Hussein S; Al-Khayat S; Tashkandi H; Al-Maghrabi J; Al-Thubaiti F; Hussein IR; Koumosani T; Shaer N; Chaudhary AG; Abuzenadah AM; Al-Qahtani MH; Dallol A
    BMC Genomics; 2015; 16 Suppl 1(Suppl 1):S3. PubMed ID: 25923920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple gene sequencing for risk assessment in patients with early-onset or familial breast cancer.
    Lin PH; Kuo WH; Huang AC; Lu YS; Lin CH; Kuo SH; Wang MY; Liu CY; Cheng FT; Yeh MH; Li HY; Yang YH; Hsu YH; Fan SC; Li LY; Yu SL; Chang KJ; Chen PL; Ni YH; Huang CS
    Oncotarget; 2016 Feb; 7(7):8310-20. PubMed ID: 26824983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Whole-exome sequencing in a Japanese family with highly aggregated diabetes identifies a candidate susceptibility mutation in ADAMTSL3.
    Jambaljav B; Tanaka D; Nagashima K; Harashima SI; Harada N; Harada T; Fujiwara Y; Wang Y; Liu Y; Tabara Y; Matsuda F; Koizumi A; Inagaki N
    Diabetes Res Clin Pract; 2018 Jan; 135():143-149. PubMed ID: 29162515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exome sequencing covers >98% of mutations identified on targeted next generation sequencing panels.
    LaDuca H; Farwell KD; Vuong H; Lu HM; Mu W; Shahmirzadi L; Tang S; Chen J; Bhide S; Chao EC
    PLoS One; 2017; 12(2):e0170843. PubMed ID: 28152038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exome sequencing reveals frequent deleterious germline variants in cancer susceptibility genes in women with invasive breast cancer undergoing neoadjuvant chemotherapy.
    Ellingson MS; Hart SN; Kalari KR; Suman V; Schahl KA; Dockter TJ; Felten SJ; Sinnwell JP; Thompson KJ; Tang X; Vedell PT; Barman P; Sicotte H; Eckel-Passow JE; Northfelt DW; Gray RJ; McLaughlin SA; Moreno-Aspitia A; Ingle JN; Moyer AM; Visscher DW; Jones K; Conners A; McDonough M; Wieben ED; Wang L; Weinshilboum R; Boughey JC; Goetz MP
    Breast Cancer Res Treat; 2015 Sep; 153(2):435-43. PubMed ID: 26296701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rescreening for genetic mutations using multi-gene panel testing in patients who previously underwent non-informative genetic screening.
    Frey MK; Kim SH; Bassett RY; Martineau J; Dalton E; Chern JY; Blank SV
    Gynecol Oncol; 2015 Nov; 139(2):211-5. PubMed ID: 26296696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic Diagnosis via Whole Exome Sequencing in Taiwanese Patients with Hypertriglyceridemia.
    Chiou KR; Chen CY; Charng MJ
    J Atheroscler Thromb; 2015; 22(9):887-900. PubMed ID: 25843152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.